l e t t e r S Polycystic kidney disease (PKD) represents a family of genetic disorders characterized by renal cystic growth and progression to kidney failure 1 . No treatment is currently available for people with PKD, although possible therapeutic interventions are emerging [2] [3] [4] [5] [6] [7] [8] . Despite genetic and clinical heterogeneity, PKDs have in common defects of cystic epithelia, including increased proliferation, apoptosis and activation of growth regulatory pathways 1 . Sphingolipids and glycosphingolipids are emerging as major regulators of these cellular processes 9 . We sought to evaluate the therapeutic potential for glycosphingolipid modulation as a new approach to treat PKD. Here we demonstrate that kidney glucosylceramide (GlcCer) and ganglioside GM3 levels are higher in human and mouse PKD tissue as compared to normal tissue, regardless of the causative mutation. Blockade of GlcCer accumulation with the GlcCer synthase inhibitor Genz-123346 effectively inhibits cystogenesis in mouse models orthologous to human autosomal dominant PKD (Pkd1 conditional knockout mice) and nephronophthisis (jck and pcy mice). Molecular analysis in vitro and in vivo indicates that Genz-123346 acts through inhibition of the two key pathways dysregulated in PKD: Akt protein kinase-mammalian target of rapamycin signaling and cell cycle machinery. Taken together, our data suggest that inhibition of GlcCer synthesis represents a new and effective treatment option for PKD.
PKD is transmitted as an autosomal dominant (AD) or autosomal recessive (AR) trait. Mutations in polycystin-1 and polycystin-2 are responsible for ADPKD, the most common form of PKD 1, 10, 11 . Recessive forms of PKD include ARPKD, a childhood disease, and nephronophthisis, the most frequent genetic cause of end-stage renal disease in the first three decades of life 11, 12 . Although multiple forms of PKD have differing clinical manifestations, common mechanisms promote cystogenesis at the cellular and molecular levels 1 .
The products of the various genes mutated in PKD are expressed in primary cilia or centrosomes 12 . Multiple molecular mechanisms contribute to PKD, including aberrant cilia-cell cycle signaling, intracellular calcium dysregulation, Wnt pathways, cAMP-activated proliferation and the Akt-mammalian target of rapamycin (mTOR) pathway [13] [14] [15] [16] . Enhanced understanding of these mechanisms and development of animal models orthologous to human ADPKD, ARPKD and nephronophthisis has led to the discovery of new potential therapies 1, 17 . At present, there is no mechanism-based treatment available for PKD.
Sphingolipids and glycosphingolipids regulate many cellular processes, including proliferation, apoptosis and modulation of cell signaling pathways [18] [19] [20] [21] . It is becoming increasingly recognized that glycosphingolipids have key roles in the progression of a number of diseases, including diabetes and cancer 18 . Glycosphingolipids are key components of membrane rafts, modulating cell surface receptors, including the epidermal growth factor, insulin and insulin-like growth factor-1 receptors [22] [23] [24] [25] . Alterations of glycosphingolipid metabolism, with elevated GlcCer and lactosylceramide (LacCer) abundance, have been documented in human ADPKD and the cpk mouse model, suggesting a role in cystogenesis 19, 26 . LacCer can act as a growth factor on kidney epithelial cells, thereby directly contributing to cystogenesis 19 . Recently, the gangliosides GM3 and GM1 were detected in primary cilium of epithelial cells 27 . Therefore, changes in glycosphingolipid metabolism in cystic epithelial cells may have a major role in driving cyst growth.
We hypothesized that inhibiting glycosphingolipid synthesis and lowering the abundance of GlcCer and its derivatives with specific GlcCer inhibitors might effectively treat PKD. We used Genz-123346, an orally available inhibitor of GlcCer synthase that shares some structural features with previously developed compounds and blocks the conversion of ceramide to GlcCer [28] [29] [30] . A consequence of inhibiting GlcCer is decreased expression of downstream lipids, including GM3, which has been linked to a positive effect on glycemic control in rodent models of diabetes 30 . A similar compound very effectively Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models reduced GlcCer accumulation in preclinical models of Gaucher's disease and was well tolerated in phase 1 and 2 clinical trials 31, 32 .
To determine whether abnormal glycosphingolipid metabolism is a common feature of PKD, we compared GlcCer and GM3 levels in normal and cystic kidneys of human ADPKD, its orthologous Pkd1 conditional knockout mouse model and jck and pcy mice orthologous to human nephronophthisis [33] [34] [35] (Fig. 1) . We observed significantly increased GlcCer and GM3, but not ceramide, abundance in all cystic samples analyzed compared to normal controls (Fig. 1b) . These data reveal that altered glycosphingolipid metabolism is a hallmark of human and mouse PKD and may be mechanistically involved in dysregulation of cell cycle progression and proliferation. If so, lowering GlcCer abundance by specifically targeting GlcCer synthase should directly affect cell cycle progression in vitro. Indeed, depletion of GlcCer and GM3 from cultured rat kidney epithelial cells with either Genz-123346 or GlcCer synthase-specific siRNA delayed cell cycle progression ( Supplementary Fig. 1 ).
We reasoned that reducing GlcCer levels by treatment with the GlcCer synthase inhibitor Genz-123346 may block cell cycle and proliferation and attenuate cystogenesis in vivo. We gave jck mice 0.1% or 0.2% Genz-123346 in their feed from 4 to 9 weeks of age. Genz-123346 treatment resulted in a dose-dependent reduction of renal GlcCer and GM3 levels ( Fig. 2a) that translated into effective inhibition of cystic disease (Fig. 2b,c and Supplementary Table 1 ). Because PKD develops over the life of an individual, safety is a major consideration. Genz-123346 was generally well tolerated in mice, although we noted a slight reduction in body weight gain at the highest dose (Supplementary Table 1 ). Notably, efficacy was achieved at lower doses as well, with no associated body weight loss (Supplementary Table 1) . A similar compound has recently proven to be well tolerated in people with Gaucher's disease in phase 1 and 2 clinical trials 32 .
We have previously shown that mechanisms of cystogenesis in jck mice have multiple similarities to human ADPKD, including activation of mitogenic signaling pathways, dysregulated cell cycle and increased apoptosis 33, 36 . To determine primary molecular targets affected by glycosphingolipid modulation in response to Genz-123346 in vivo, we acutely treated jck mice with established disease (7 weeks of age) with Genz-123346 for only 5 d (Fig. 3a-d The de novo synthesis of sphingolipids is a multistep process that results in the production of ceramide from serine and palmitoyl-CoA. Ceramide can be deacylated by ceramidase to generate sphingosine, which can be phosphorylated by sphingosine kinase to generate sphingosine-1-phosphate. Alternatively, ceramide can be converted to or generated from sphingomyelin, a membrane lipid, or glycosylated by UDP-glucose:ceramide glucosyltransferase (GlcCer synthase) to generate GlcCer. GlcCer can be further modified by the addition of galactose to LacCer, which can be modified by GM3 synthase to GM3. GM3 can subsequently be modified to generate other gangliosides. Genz-123346 is a direct inhibitor of GlcCer synthase. (b) Kidney GM3, GlcCer and ceramide levels measured by liquid chromatography-mass spectrometry analysis in human ADPKD, 24-day-old Pkd1 conditional knockout (cKO) mice (deleted on P1 and P2), 9-week-old jck mice and 30-week-old pcy mice relative to normal controls. AU = arbitrary units. Data are expressed as means ± s.e.m. n = 10 humans with PKD and 3 normal humans; n = 3 for all mouse samples. *P < 0.05 compared to control.
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l e t t e r S affecting cystic growth (data not shown). Therefore, we could assess primary targets responsible for the treatment effects. Western blot analysis of treated kidneys showed a direct effect of Genz-123346 on the cell cycle machinery, as evidenced by reduced cyclin D expression and reduced Rb phosphorylation, suggesting G1/S cell cycle arrest (Fig. 3b) . Reduced proliferating cell nuclear antigen (PCNA) levels confirmed the inhibitory effect of Genz-123346 on proliferation (Fig. 3b) . This mechanistic effect of GlcCer synthase inhibition might be responsible for its therapeutic efficacy in PKD, as we have previously demonstrated that direct blockade of the cell cycle with the CDK inhibitor roscovitine results in a robust arrest of PKD in preclinical models 2 . A large body of evidence suggests that glycosphingolipids play a key part in mediating cell proliferation 9 . Exogenous LacCer can increase kidney proximal tubular cell proliferation 19 . Also, increasing GlcCer levels in Madin-Darby canine kidney cells with a β-glucosidase inhibitor promotes proliferation, whereas inhibition of GlcCer synthase activity with 1-phenyl-2-decanoylamino-3-morpholino-1-propanol hydrochloride (PDMP) decreases proliferation 37 . PDMP treatment of NIH3T3 cells also results in effective inhibition of proliferation through blockade of the cell cycle 20 . We also observed a direct effect of Genz-123346 on the Akt-mTOR signaling pathway, with reduced phosphorylation of Akt and ribosomal protein S6 (Fig. 3d and Supplementary Fig. 2) . Furthermore, mTOR has also been validated as a target for PKD through multiple preclinical trials 3, 7, 8 . In contrast, apoptosis or mitogen-activated protein kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) signaling were not directly affected by Genz-123346 (Fig. 3c,d) .
Because primary targeting of the Akt-mTOR and cell cycle pathways by Genz-123346 may indirectly affect other pathways of cystogenesis upon chronic treatment, we analyzed the long-term effects of GlcCer synthase inhibition in jck mice treated with Genz-123346 from 4 to 9 weeks (Fig. 3e-h) . In addition to the inhibition of the cell cycle and Akt-mTOR pathways, chronic administration of Genz-123346 indirectly inhibited apoptosis and MEK-ERK signaling in jck kidneys (Fig. 3g,h) . Of note, Genz-123346 had no effect on any molecular pathway analyzed in wild-type treated kidneys, suggesting its effect is limited to diseased kidneys (Fig. 3f-h) .
To determine whether cyst-lining cells are responsible for elevated glycosphingolipid levels in diseased kidneys, we derived immortalized epithelial cells from wild-type and jck kidneys. Cultured cystic cells showed high expression of GlcCer synthase mRNA ( Supplementary   Fig. 3a ) and elevated GlcCer and GM3 levels ( Supplementary  Fig. 3b ) compared to wild-type cells. Notably, Akt-mTOR signaling was activated in cultured cystic cells and was attenuated in response to Genz-123346 treatment (Supplementary Fig. 3c ). The in vitro data support the idea that altered glycosphingolipid metabolism modulates cell signaling and proliferation cell autonomously in kidney epithelial cells. Although our data support a link between aberrant glycosphingolipid synthesis and cystogenesis, the exact mechanisms are largely unknown and need to be investigated.
To further evaluate whether GlcCer synthase inhibition can effectively treat a slowly progressive, adult form of PKD characterized by cyst formation and fibrosis, we tested efficacy in pcy mice with 0.2% Genz-123346 in feed between 4 and 15 weeks of age. Genz-123346 lowered kidney GlcCer and GM3 abundance (Fig. 4a) and effectively inhibited cystogenesis and fibrogenesis in pcy mice (Fig. 4b-d and Supplementary Table 2) . Therefore, inhibition of GlcCer synthase activity retards PKD progression in two different models of nephronophthisis.
To strengthen the argument for glycosphingolipid modulation as a new therapeutic strategy for ADPKD, we tested Genz-123346 efficacy in an orthologous mouse model with a conditionally inactivated Pkd1 gene. Such models have only recently been produced, and confirmatory trials of drugs shown to be effective in nonorthologous models are emerging 4, 8 . We generated mice with a germline null allele for Pkd1 (Pkd1 tm1Gzbd ), a conditional knockout allele with lox sites flanking exons 21-23 (Pkd1 tm1Gztn ) and a tamoxifen-regulatable Cre gene 36, 38 . Cystogenesis was induced by injecting tamoxifen into nursing females at postnatal day 5 (P5) and progressed with renal functional decline over 4-5 weeks. Genz-123346 treatment between day 7 and day 33 significantly lowered kidney GlcCer and GM3 amounts (Fig. 4e) and inhibited cystogenesis, as evidenced by reduced kidney to body weight ratio, cystic volume and blood urea nitrogen (BUN) (Fig. 4f,g and Supplementary Table 3) .
The data presented here show that glycosphingolipid metabolism is altered in jck and pcy mouse models of nephronophthisis and the Pkd1 conditional knockout mouse model of ADPKD. Inhibition of GlcCer synthase alters glycosphingolipid metabolism and effectively blocks disease progression in mouse PKD. Mechanism-of-action studies suggest that GlcCer synthase inhibition results in effective cell cycle arrest and inhibition of the Akt-mTOR pathway, ultimately leading to decreased apoptosis and mitogenic signaling. Together, these results 
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